argenx SE operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares argenx SE with three other
miscellaneous service companies in Europe:
Innate Pharma S.A.
of FRANCE
(2019
sales of 68.97 million Euros [US$80.77 million]
of which 100%
was conducting R&D on pharmaceutical produc),
Oxford BioMedica plc
of UNITED KINGDOM
(£64.06 million [US$81.61 million]
of which 80%
was Platform), and
MorphoSys AG
which is
based in GERMANY
(71.76 million Euros [US$84.02 million]
of which 52%
was Partnered Discovery).
Sales Analysis.
Sales increased substantially in 2019:
argenx SE reported sales of 69.78 million Euro (US$81.71 million)
for the
year ending
December of 2019.
This
represents
an
increase of 224.8%
versus 2018, when the company's sales were 21.48 million Euro.
Sales of Research and Development Service Fees (F saw an increase
that was more than double the company's growth rate: sales were up
1,274.4% in 2019, from
1.41 million Euro to 19.34 million Euro.